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Abstract
Study Objectives: Insomnia is associated with elevated levels of suicidal thoughts and behaviors. Emerging evidence suggests that
cognitive-behavioral therapy for insomnia (CBTI) may reduce suicidal ideation (SI). However, the role of digital therapeutics in both the
alleviation and prevention of SI remains unclear, and treatment mechanisms facilitating SI reductions have not been clearly identified.
Methods: A total of 658 adults with Diagnostic and Statistical Manual of Mental Disorders, 5th Edition insomnia disorder enrolled in a
single-site randomized controlled trial evaluating the efficacy of digital CBTI relative to attention control. Outcomes were measured
at pretreatment, posttreatment, and 1-year follow-up.
Results: Before treatment, 126 patients endorsed SI (19.1% prevalence). Among those with baseline SI, CBTI patients reported lower SI
rates at posttreatment (30.0% vs 54.5%, p = .005) and 1-year follow-up (29.6% vs 46.8%, p = .042) relative to control. PRODCLIN analysis
estimated that half of suicidolytic effects of CBTI were mediated through insomnia remission. Among those without baseline SI, CBTI
did not directly prevent new onset SI. However, insomnia remitters reported lower rates of new-onset SI at posttreatment relative to
non-remitters (1.5% vs 6.5%, p = .009). Mediation analysis supported a significant indirect effect wherein CBTI increased the likelihood
of insomnia remission, which was associated with SI prevention (αβ = −3.20, 95% CI = −5.74 to −0.87).
Conclusion: Digital CBTI reduces insomnia symptoms, which promotes SI alleviation and prevention. For nonsuicidal patients, digital CBTI
may serve as a highly accessible monotherapy for improving sleep, thereby reducing the risk for SI. For suicidal patients, digital CBTI may be
appropriately administered as an adjunct treatment to support mainline intervention more directly targeting suicidogenic thoughts.
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Cognitive-behavioral therapy for insomnia prevents and alleviates suicidal ideation:
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Statement of Significance

Introduction
According to the Centers for Disease Control and Prevention
(CDC), suicide was the 12th leading cause of death in the United
States across all ages in 2020 [1]. CDC statistics show that suicide ranged between being the second and fourth leading cause
of death for age groups within adolescence, young adulthood,
and middle adulthood. To help curb suicide rates, researchers
have identified demographic and clinical risk factors for suicidal
thoughts and behaviors. The identification of modifiable factors
associated with suicidality can provide targets for intervention
to alleviate or even prevent suicidal thoughts and behaviors.
Traditionally, these risk factors have centered on mood disorders,
substance abuse disorders, and major physical health conditions
as well as access to lethal means [2–6]. However, a burgeoning
literature indicates that insomnia represents a critical—and historically overlooked—risk factor for suicidality [7, 8].
Meta-analytic data on sleep and suicidality reveal that insomnia is associated with an increased risk for suicidal ideation (SI),
suicide attempts, and suicide [9, 10]. Critically, the association
between insomnia and SI is significant and substantial even
when adjusting for depression and other mental health conditions [11–13]. Notably, among depressed individuals, insomnia is
a unique and robust indicator of SI intensity [14]. As insomnia
prospectively predicts future SI [15–17], suicide-related outcomes
have gained interest in clinical trials for insomnia.
An emerging literature suggests cognitive-behavioral therapy
for insomnia (CBTI) decreases SI in patients with insomnia. In
the first insomnia trial examining SI as an outcome, Manber and
colleagues published data from 301 adults who participated in
seven (90-minute) group CBTI sessions [18]. In this trial, 23% of
patients endorsed SI before treatment, but SI rates decreased to
10% post-treatment. In replication of these study findings, Trockel
et al. showed that SI rates decreased from 32% at pretreatment to
21% at posttreatment in 647 Veterans with insomnia who received
in-person CBTI in an individual format [19]. In a randomized controlled trial (RCT), Pigeon and colleagues showed that brief CBTI
(delivered face-to-face in primary care) reduced SI intensity in 54
Veterans with insomnia [20].
Not only does CBTI reduce SI, but the two latter trials also
reported associations between insomnia alleviation and decreases
in SI, thereby offering preliminary support that insomnia reduction may represent a key mechanism by which CBTI affects SI [19,
20]. In the Trockel study, each 7-point reduction in the insomnia
severity index (ISI) during CBTI was associated with a 65% reduction in odds of SI.
Although the greatest support for insomnia therapeutics
serving a role in suicide-risk management centers on CBTI, it
is notable that a recent RCT evaluated the suicidolytic effects
of zolpidem-CR (i.e. zolpidem extended release) in a sample of
suicidal patients with major depression starting antidepressant

medication [21]. In this trial, patients were randomized to either
adjunct zolpidem-CR or placebo. Zolpidem-CR yielded a significant treatment effect on one of two SI indices. Importantly, SI
reductions were associated with decreases in insomnia symptoms, thereby lending further preliminary support that insomnia
alleviation may represent a viable treatment target to reduce suicide-related outcomes.
As scientific inquiry into the role of insomnia therapeutics in
suicide management is still in its early stages, there remain several unknowns. First, as healthcare moves increasingly into the
digital realm, it is important to determine whether digital CBTI
has efficacy for reducing suicide-related outcomes. We know of
only one clinical trial that published data on the effects of digital
CBTI on SI [22]. In 2020, our team showed that 5.5% of pregnant
patients with insomnia endorsed SI before treatment. After treatment, 0.0% of CBTI patients endorsed SI, whereas 6.7% of controls
endorsed SI. While the treatment effect approached significance
(p = .054) suggesting that digital CBTI may reduce SI, we were ultimately underpowered to detect significance in posttreatment SI
rates in a sample of 91 patients.
Second, prior trials examining the suicidolytic effects of CBTI
have included patients with and without baseline SI in a single
sample. As a result, these studies have tested CBTI effects on alleviation (for patients with baseline SI) and prevention (for patients
without baseline SI) simultaneously. However, examining CBTI's
effects on SI separately in these subgroups may produce more
nuanced knowledge regarding the potential effects of CBTI for
alleviating and preventing SI, respectively.
Third, several studies have shown that reducing insomnia is
associated with reductions in SI [19–21], which yields promising preliminary support for insomnia alleviation as a key treatment mechanism for reducing SI. Indeed, accumulating evidence
from observational studies shows that nocturnal wakefulness
increases risk of suicide [23, 24], and suicides most often occur at
night [25]. Thus, interventions aimed to reduce nocturnal wakefulness may yield clinically meaningful effects on suicide-related
outcomes. Yet, no RCT has empirically tested an indirect effect
of CBTI on suicide outcomes as mediated by insomnia symptom alleviation, which would offer strong support for alleviating
insomnia to reduce suicidality.
The present study is a secondary analysis of RCT data testing
the efficacy of digital CBTI, relative to digital sleep education control, on SI. The sleep education control condition included psychoeducation on sleep as well as sleep hygiene tips. We selected
sleep education as the control comparator due to the common
role of sleep hygiene education serving as nonpharmacological
treatment as usual in real-world clinical settings. Unique to this
RCT, we separated the full sample into two subgroups: patients
with and without baseline SI. We predicted that: (Hypothesis
1A) CBTI would alleviate SI relative to control in patients with
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Individuals with insomnia report high rates of suicidal thoughts. Early evidence suggests that cognitive-behavioral therapy for
insomnia (CBTI) may reduce suicidal thoughts in insomnia patients. Unfortunately, many individuals with insomnia do not have
access to CBTI providers, thus creating a need for improving care access. Digital CBTI (delivered via an automated and interactive
online program) is highly accessible and has been shown to be effective and safe for treating insomnia. However, it is unclear
whether suicidolytic effects of CBTI are preserved in its digital format. Our trial showed that treating insomnia to remission with
digital CBTI alleviates and prevents suicidal ideation. This study is the first to support treating insomnia as a potentially viable
strategy in suicide prevention efforts.
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Methods
Study setting and recruitment
Study data were obtained from the Sleep to PRevent Evolving
Affective Disorders (SPREAD) trial (NCT02988375). The study setting was Henry Ford Health (HFH) in southeastern Michigan. HFH
is centrally located in Metro Detroit and includes six hospitals
and over 30 outpatient medical centers. Additionally, HFH owns a
major health insurance company (Health Alliance Plan). Patients
were recruited for HFH hospitals, outpatient clinics, and insurance patient registries. Recruitment occurred in 2016 and 2017
via internet-based methods including clinic databases, health
system-wide email newsletters, and existing research databases
(e.g. previous research patients who expressed interest in future
studies). All study participants provided informed consent prior
to participating. Study procedures were approved by the HFH
institutional review board.

Study eligibility
Interested patients completed an online screening survey
(Qualtrics, Provo, UT) that assessed for study eligibility. Inclusion
criteria included Diagnostic and Statistical Manual of Mental Disorders,
5th Edition (DSM-5) [26] diagnostic criteria for chronic insomnia
disorder and being ≥18 years of age. Exclusion criteria included
patient-reported sleep disorder diagnoses other than insomnia
(e.g. restless legs and narcolepsy), untreated obstructive sleep
apnea (OSA; treated OSA was OK), diagnosed bipolar disorder,
diagnosed seizure disorder, and chronic depression symptoms;
see Table 1.

Study design and participants
This was a RCT with simple randomization into two parallel arms
of either digital CBTI or digital sleep education control (see details
below). Randomization was computerized and automated centrally
through Qualtrics immediately after participants met eligibility
criteria. A total of 1385 adults with insomnia disorder from Metro
Detroit were enrolled and randomized to digital CBTI or control at a
2:1 ratio due to higher anticipated attrition for active versus control
conditions as previously demonstrated in digital intervention studies [27]. A total of 658 patients engaged in CBTI or control treatment.
Of these 658 patients, 139 (21.1%) identified as male, and 126 (19.1%)
endorsed SI before CBTI. Most patients identified as non-Hispanic
White or Black (92.7%). See Figure 1 for the enrollment flow chart
and refer to the “Sample characteristics” of the Results.

Interventions
Digital CBTI
Patients randomized to CBTI completed the Sleepio program
via the internet (www.sleepio.com, Big Health Inc.). Sleepio is
among several currently available digital CBTI programs and was
selected for this study because it is evidence-based, standardized,
fully automated, and has been tested in multiple RCTs comprising several thousand patients including several of our own trials
[22, 28–37]. Patients received access for 12 weeks during which
they could complete the six sessions; each session was unlocked
on a weekly basis, and patients were advised to complete one session per week. The intervention covered behavioral components
(sleep restriction, stimulus control), cognitive components (e.g.
cognitive restructuring, paradoxical intention), progressive muscle relaxation, and sleep hygiene. Sessions were directed by an
animated “virtual therapist” who reviews and guides the progress
of the patient based on submitted sleep data. Participants were
granted access to new sessions weekly (i.e. new sessions became
available a week after completing a previous session).

Digital sleep education control
Patients randomized to the online sleep education condition
received six weekly emails based on the National Institutes of

Table 1. Eligibility criteria
Inclusion

Exclusion

1. DSM-5 insomnia disorder

1. Sleep disorders (other than insomnia), for example, restless legs syndrome, narcolepsy, central sleep
apnea, and untreated obstructive sleep apnea (OSA; treated OSA was not exclusionary)

2. Age 18 years or older

2. Bipolar disorder
3. Epilepsy or other seizure disorder
4. High depression chronicity
Insomnia disorder was survey assessed and determined per DSM-5 criteria. Exclusionary items were reported by patients on an online screener. Specifically,
patients were asked to report diagnosed sleep disorders, diagnosed bipolar, and diagnosed seizure disorders. Depression chronicity was operationalized as selfreported daily or near-daily depressed mood and anhedonia.

CBTI

Received Study
Adversement
N=25,015

Randomized
N=1,358
Excluded
N=23,491

- Ineligible (n=2,051)
- Did not respond to ad (n=21,440)

Figure 1. Study flow chart.

CBTI

N=946
- Did not engage (i.e., no-show; n=508)
- Withdrew (n=80)

N=358

Sleep Educaon Control

Sleep Educaon Control

N=439
- Withdrew (n=139)

N=300
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baseline SI, and that (Hypothesis 1B) mediation analyses would
support a significant indirect effect wherein CBTI predicts insomnia remission, which, in turn, predicts reduced SI. Similarly, we
predicted that (Hypothesis 2A) CBTI would prevent SI relative to
control in patients without baseline SI, and that (Hypothesis 2B)
mediation analyses would support a significant indirect effect
wherein CBTI predicts insomnia remission, which, in turn, predicts SI prevention.
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Study outcomes
Study outcomes were assessed a week before treatment, 1 week
after treatment, and then 1-year after their completed posttreatment assessment.
Suicidal ideation (SI) served as our primary end-point. SI was
assessed using the Quick Inventory of Depressive Symptomatology,
a 16-item self-report survey (QIDS-SR16), which measures symptoms over the prior 7 days [43]. Specifically, any endorsement of
the “thoughts of death or suicide” item was operationalized as
an endorsement of SI. We also used the QIDS-SR16 total score to
measure overall depressive symptoms for descriptive purposes.
Scores range from 0 to 27 with higher scores indicating greater
depression. QIDS-SR16 ≥ 11 indicates moderate depression.
The ISI was used to assess insomnia symptoms, which measures symptoms over the prior 2 weeks [44]. Higher scores on the
ISI reflect greater insomnia severity with ISI scores ≥ 11 indicating clinical symptom severity. In treatment studies, ISI scores ≤ 7
after treatment indicate insomnia remission [44].

Analysis plan
All statistical analyses were performed using SPSS 26 and R 4.2.1.
All inferential tests were two-sided with a significance level of
alpha = 0.05. We first presented descriptive data for pretreatment
sample characteristics, including sociodemographic information
and presenting clinical symptoms. We then split the sample into
two subgroups: Patients who presented with pretreatment SI and
those who denied SI before treatment. Before testing our hypotheses, we compared patients with and without pretreatment SI
on sociodemographics and clinical symptoms for descriptive
purposes.

α

INSOMNIA
REMISSION
αβ represents the indirect
(mediated) effect

CBTI

β
SUICIDAL
IDEATION

Figure 2. Hypothesized mediation model wherein cognitive-behavioral
therapy for insomnia (CBTI) effects on suicidal ideation (SI) are
mediated by insomnia remission. α represents the effect of treatment
on the mediator (IV → M). β represents the effect of the mediator on
the outcome (M → DV) while controlling for the effects of treatment.
The product of these parameters (αβ) represents the indirect effect of
treatment on the outcome through the mediator (IV → M → DV). If the
95% CI of αβ does not overlap with zero, then mediation is inferred.

We then tested the indirect (i.e. mediated) effect. For the alpha
path (IV → M), we regressed insomnia remission onto treatment
condition. This regression model determines whether CBTI
increases the odds of insomnia remission relative to control.
For the beta path (M → DV), we regressed posttreatment SI onto
insomnia remission, while controlling for treatment condition.
This model determines whether insomnia remission (M) is associated with SI outcomes (DV) while controlling for CBTI effects
(IV). In this model, the effect of CBTI on SI becomes τʹ, which is
the effect of the IV on the DV while controlling for the mediator.
From these regression models, the product of the α and β
parameter estimates represent the indirect (i.e. mediated) effect.
The confidence intervals (CIs) of the indirect effect (αβ) were
estimated using the PRODCLIN method in R 4.0.2 using the
RMediation library [45]. This method does not assume a normal
distribution, yields asymmetric CIs, and is more accurate than
traditional significance tests. If the 95% CI for the indirect effect
does not include zero, then significant mediation is inferred. Refer
to Figure 2 for visual depiction of the mediation model. If the
direct effect was significant, then we can estimate the proportion
of the direct effect that is mediated by the indirect effect with the
following equation: (τ − τʹ)/τ.

SI prevention.
These analyses were conducted in patients who denied SI at
baseline. Otherwise, the analytic steps were the same as the SI
alleviation analyses described above.

SI alleviation.

Per protocol and modified intent-to-treat analyses.

We first evaluated whether CBTI alleviated SI in patients who presented with pretreatment SI. Using a logistic model, we regressed
posttreatment SI on the treatment condition. We then conducted
a 2 × 2 chi-square to report SI rates for each treatment group for
post hoc descriptive purposes. This process was then repeated for
1-year follow-up.
Next, we tested whether insomnia remission mediated the
effects of CBTI on SI alleviation. Here, we describe mediation
using the terms independent variable (IV), dependent variable
(DV), and mediator (M). The direct effect (also known as the tau
(τ) path) refers to the IV → DV effect; this path is reflected by the
first logistic regression model described above wherein posttreatment SI was regressed onto treatment condition. This regression
model determines that CBTI decreases odds SI relative to control.
Although a direct effect of the CBTI (IV) on SI (DV) is not necessary for mediation, the determination of a direct effect is nevertheless informative.

No study outcomes data were missing at posttreatment, and
we retained 92.4% of patients at 1-year follow-up (n = 608/658).
Due to attrition, all 1-year follow-up analyses were performed
using two approaches: (1) per-protocol analysis and (2) intentto-treat (ITT) using imputed data. Follow-up data were largely
consistent between both approaches. Results reported below are
for the per-protocol analysis, which presents group SI rates that
are unaffected by data imputation. We report methodology and
results related to the ITT approach for 1-year follow-up analyses
in the Supplement.

Results
Sample characteristics
We observed a wide range of ages from 18 to 92 years. The sample
was predominately female (78.9%), and patients who identified
racially as non-Hispanic White (71.4%) and non-Hispanic Black
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Health guide to healthy sleep [38]. Information was provided on
the basics of sleep regulation; relationships between sleep and
health problems such as obesity, diabetes, and cardiovascular
disease; effects of sleep-disruptive substances such as caffeine,
nicotine, and alcohol; and tips on creating a sleep-conducive bedroom environment. Sleep education was selected as the control
condition because psychoeducation and sleep hygiene are common in clinical practice, especially in primary care [39, 40], and
also because they are commonly used as an attention control in
clinical trials of insomnia. Importantly, neither sleep education
nor sleep hygiene is considered an effective standalone treatment
for insomnia [41]. We have utilized sleep education as our attention control in previous RCTs [22, 42].
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Does CBTI alleviate SI?
To test CBTI's effects on alleviating SI, we first analyzed data
from the 126 patients who endorsed SI prior to treatment, which
involved comparing 60 CBTI patients to 66 controls.

Posttreatment.
Logistic regression showed that CBTI was associated with lower
likelihood of SI after treatment relative to control (Odds Ratio
[OR] = 0.36, 95% CI = 0.17 to 0.75, p = .006). Specifically, 30.0% (n =
18/60) CBTI patients endorsed SI after treatment, whereas 54.5%
(n = 36/66) controls endorsed SI after treatment, thereby indicating that controls with pretreatment SI were nearly twice as likely
to continue endorsing SI after treatment relative to CBTI patients
with pretreatment SI (χ2 = 7.73, p = .005, RR =1.82; Table 3).

One-year follow-up.
Logistic regression again showed that CBTI patients, relative to controls, were at lower odds of reporting SI a year after treatment (OR =
0.46, 95% CI = 0.21 to 0.98, p = .044). Specifically, 29.6% (n = 16/56)

CBTI patients endorsed SI a year after treatment relative to 46.8%
(n = 29/62) controls, thereby indicating that controls with pretreatment SI were 1.5 times as likely to continue endorsing SI a year after
treatment relative to CBTI patients (χ2 = 4.13, p = .042, RR = 1.58).

Insomnia remission as a CBTI mechanism in SI
alleviation
Alpha path: Treatment →Insomnia remission.
Logistic regression revealed that CBTI patients were at substantially greater odds of remitting from insomnia at posttreatment
than controls (b = 2.57, SE = 0.50, OR = 13.08, 95% CI = 4.90 to
34.93, p < .001). Among CBTI patients with pretreatment SI, 56.7%
(n = 34/60) of these patients remitted from insomnia at posttreatment. By comparison, just 9.1% (n = 6/66) of controls with pretreatment SI remitted from insomnia after treatment.

Beta path: Insomnia remission → SI.
Logistic regression revealed that insomnia remitters were at
substantially lower odds of endorsing SI after treatment relative
to non-remitters (b = −1.26, SE = 0.50, OR = 0.28, 95% CI = 0.11
to 0.76, p = .012). Notably, treatment condition was no longer
significant after accounting for the effects of insomnia remission (b = −0.50, OR = 0.61, 95% CI = 0.26 to 1.40, p = .243). A post
hoc chi-square analysis revealed that, irrespective of treatment
condition, insomnia non-remitters were 2–3 times more likely
to endorse SI relative to insomnia remitters; see Table 3 for SI
rates.

Indirect path: Treatment → Insomnia remission → SI.
The PRODCLIN estimate of the indirect effect supported mediation (αβ = −3.30, SE = 1.59, 95% CI = −6.78 to −0.60) whereby CBTI

Table 2. Pretreatment sample characteristics for the full sample and by pretreatment SI status

Age (M ± SD, range)

Full sample

No baseline SI

Baseline SI

n = 658

n = 532

n = 126

45.03 ± 15.42

45.89 ± 15.22

41.37 ± 15.81

Test statistic, p-value, and effect size

t(656) = −2.98, p = .003, d = 0.29

139; 21.1%

103; 19.4%

36; 28.6%

χ2 = 5.19, p = .023, RR = 1.47

White

470; 71.4%

382; 71.8%

88; 69.8%

χ2 = 0.18, p = .672

Black

140; 21.3%

116; 21.8%

24; 19.0%

Note: chi-square analysis compared SI rates between
White and Black as they were the most wellrepresented groups.

Male sex (n; %)
Race (n;%)

Unreported

20; 3.0%

14; 2.6%

6; 4.8%

Asian

12; 1.8%

8; 1.5%

4; 3.2%

Multiracial

12; 1.8%

9; 1.7%

3; 2.4

4; 0.6%

3; 0.6%

1; 0.8%

Native American

χ2 = 2.11, p = .147

Education level (n;%)
No HS or GED (<4)
HS or GED (4–7)
Associates (8)

15; 2.3%

9; 1.7%

6; 4.8%

276; 41.9%

219; 42.2%

57; 45.2%

84; 12.8%

72; 13.5%

12; 9.5%

Note: chi-square analysis compared SI rates between
patients with and without college degrees.

Bachelors (9 & 10)

172; 26.1%

144; 27.1%

28; 22.2%

Graduate degree (11–12)

111; 16.9%

88; 16.5%

23; 18.3%

Poverty (<$20K) (n;%)

140; 21.3%

95; 17.9%

45; 35.7%

ISI (M ± SD)

17.79 ± 4.29

17.67 ± 4.35

18.29 ± 4.01

t(656) = 1.46, p = .146

QIDS-SR16 (M ± SD)

10.77 ± 4.54

9.72 ± 4.07

15.21 ± 3.69

t(656) = 13.88, p < .001, d = 1.41

χ2 = 19.39, p < .001, RR = 1.99

SI, suicidal ideation over the past week, operationalized as endorsing the SI item on the quick inventory of depressive symptomatology, 16-item self-report
version; M ± SD, mean and standard deviation; n, number of patients; HS, high school; GED, General Education Development; Associates, associates degree;
Bachelors, bachelor's degree; ISI, insomnia severity index; QIDS-SR16, quick inventory of depressive symptomatology, 16-item self-report version; χ2, chi-square;
RR, relative risk; d, Cohen’s d effect size.
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(21.3%) were well-represented. Three-hundred-and-sixty-seven
(55.8%) patients reported attaining a post-secondary degree.
Of the 658 patients in the study, 19.1% (n = 126/658) endorsed
SI prior to treatment. Group comparisons showed that patients
with pretreatment SI were more likely to identify as male (relative risk [RR] = 1.47) and reported an annual household income
<$20 000 (RR = 1.99). Moreover, patients with SI reported greater
depressive symptoms (Cohen’s d = 1.41) and younger age (Cohen’s
d = 0.29). See Table 2 for comparisons of patients with and without SI before treatment. Notably, pretreatment SI rates did not
differ by race or education level.
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Table 3. SI rates by treatment condition and insomnia remission status at posttreatment and 1-year follow-up
CBTI

Control

Remission

Non-remission

Alleviating SI: Rates of SI at posttreatment and 1-year follow-up for patients who endorsed SI before treatment

Posttreatment
36/66; 54.5%

χ2 = 7.73, p = .005, RR = 1.82

8/40; 20.0%

46/86; 53.5%

χ2 = 12.50, p < .001, RR = 2.68

SI endorsed

16/56; 29.6%

29/62; 46.8%

χ2 = 4.13, p = .042, RR = 1.58

8/37; 21.6%

37/81; 53.5%

χ2= 6.23, p = .013, RR = 2.12

SI endorsed (ITT)

17/60; 28.3%

30/66; 45.5%

χ2 = 3.94, p = .047, RR = 1.61

8/43; 18.6%

39/83; 47.0%

χ2 = 9.76, p = .002, RR = 2.53

1-year follow-up

Preventing SI: Rates of SI at posttreatment and 1-year follow-up for patients who denied SI before treatment

Posttreatment
15/298; 5.0%

10/234; 4.3%

χ2 = 0.17, p = .681

3/195; 1.5%

22/337; 6.5%

χ2 = 6.87, p = .009, RR = 4.33

SI endorsed

12/270; 4.4%

15/220; 6.8%

χ2 = 1.31, p = .252

8/191; 4.2%

19/299; 6.4%

χ2 = 1.05, p = .305

SI endorsed (ITT)

14/298; 4.7%

18/234; 7.7%

χ2 = 2.08, p = .149

8/209; 3.8%

24/323; 7.4%

χ2 = 2.91, p = .088 , RR = 1.95

SI endorsed
1-year follow-up

SI, suicidal ideation over the past week, operationalized as endorsing the SI item on the quick inventory of depressive symptomatology, 16-item self-report
version; Remission, insomnia severity index score ≤ 7; Non-remission, insomnia severity index score ≥ 8. One-year follow-up data are derived from per-protocol
analysis, except when noted as ITT (intent-to-treat; these ITT results are reported in the Supplement). χ2, chi-square for comparing SI rates between treatment
conditions and between remission statuses; RR, relative risk; CBTI, cognitive-behavioral therapy for insomnia.

α=2.57,
SE=.50

Model 1: SI Allevia on

Model 2: SI Preven on

INSOMNIA
REMISSION

INSOMNIA
REMISSION

αβ=-3.30, 95%CI=-6.78, -0.60
Significant indirect effect

CBTI

β=-1.26,
SE=.50

α=1.84,
SE=.22

SUICIDAL
IDEATION

CBTI

αβ=-3.20, 95%CI=-5.74, -0.87
Significant indirect effect

β=-1.74,
SE=.64

SUICIDAL
IDEATION

Insomnia remission mediates CBTI effects on SI allevia on Insomnia remission mediates CBTI effects on SI preven on

Figure 3. Mediation results in suicidal ideation (SI) alleviation and SI prevention. α represents the effect of cognitive-behavioral therapy for insomnia
(CBTI) on insomnia remission (IV → M). β represents the effect of insomnia remission on SI (M → DV), controlling for CBTI effects. αβ represents the
indirect effect of CBTI on SI as mediated by insomnia remission.

increases odds of insomnia remission, which, in turn, decreases
odds of endorsing SI after treatment (Figure 3, model 1). The
estimated effect of CBTI on SI decreased from b = −1.03 (τ) in a
bivariate model to b = −0.50 (τʹ) when controlling for insomnia
remission. Thus, we estimated that insomnia remission mediates
51.5% of CBTI’s effect on SI reduction (τ/[τ − τʹ] = 1.03/[1.03 – 0.50]).

Does CBTI prevent SI?
To test CBTI's effects on reducing risk for developing new-onset
SI, we analyzed data from the 532 patients who denied SI prior to
treatment, which involved comparing 298 CBTI patients to 234
controls.

Posttreatment.
Contrary to the alleviation results, logistic regression showed that
posttreatment SI rates did not differ between patients in the CBTI
and control conditions (OR = 1.19, 95% CI = 0.52 to 2.69, p = .681).
See Table 3 for SI rates by treatment condition.

One-year follow-up.
Once again, logistic regression showed that CBTI was not directly
associated with the prevention of SI a year after treatment

relative to control (OR = 0.64, 95% CI = 0.29 to 1.39, p = .255). See
Table 3 for SI rates by treatment condition.

Insomnia remission as a CBTI mechanism in SI
prevention
Although CBTI did not produce a direct effect on SI prevention, it is possible that CBTI may nevertheless produce
an indirect effect on SI prevention via insomnia remission.
Indeed, significance testing of a mediation effect does not
require a significant direct effect (indicated by the 95% CI of
αβ) [46–49].

Alpha path: Treatment →Insomnia remission.
Logistic regression revealed that CBTI patients without pretreatment SI were at substantially greater odds of remitting
from insomnia at posttreatment than control patients without
pretreatment SI (b = 1.84, SE = 0.22, OR = 6.29, 95% CI = 4.13
to 9.59, p < .001). Among CBTI patients without pretreatment
SI, 53.4% (n = 159/298) of these patients remitted from insomnia at posttreatment. By comparison, just 15.4% (n = 36/234) of
controls without pretreatment SI remitted from insomnia after
treatment.
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Beta path: Insomnia remission → SI.

Indirect path: Treatment → Insomnia remission → SI.
The PRODCLIN estimate of the indirect effect supported mediation (αβ = −3.20, SE = 1.24, 95% CI = −5.74 to −0.87) whereby CBTI
increases odds of insomnia remission, which, in turn, reduces
odds of endorsing new SI after treatment for patients who denied
SI prior to treatment (Figure 3, Model 2). As CBTI did not produce
a direct effect on SI, the data suggest that CBTI prevents SI to the
extent that it produces insomnia remission.

Discussion
The present study examined the effects of digital CBTI on the alleviation and prevention of SI in 658 adults with DSM-5 insomnia
disorder. Among insomnia patients presenting to treatment with
suicidal thoughts, digital CBTI yielded strong acute and long-lasting effects on SI. Importantly, our study offers novel findings that
treating insomnia patients to remission prevents new-onset SI,
which may support expanding the role of CBTI and other insomnia therapeutics in suicide management. Overall, these clinical
trial findings suggest that digital CBTI can serve a role in alleviating and even preventing SI in insomnia patients and that
insomnia remission represents a critical treatment mechanism
by which CBTI mitigates suicide risk.

CBTI alleviates SI
Nearly 1 in 5 insomnia patients who presented to treatment in
our study endorsed SI. This prevalence rate is consistent with
prior treatment-seeking insomnia patient samples [18, 19], indicating that a substantial proportion of insomnia patients have
suicidal thoughts that deserve clinical attention.
Our findings strongly supported the effectiveness of digital
CBTI for reducing SI relative to a control condition. Among suicidal patients, we observed a 70% reduction in SI in the CBTI condition at posttreatment, which remained consistent a year later
at a 72% reduction. In the control condition, we observed just a
45% reduction in SI at posttreatment, which slightly increased to
a 53% reduction from baseline at follow-up. Moreover, we estimated that insomnia remission mediated approximately half of
the effect of CBTI on SI, thereby identifying insomnia remission as
a key treatment mechanism by which CBTI alleviates SI. Overall,
the findings are highly consistent with prior studies supporting
the effectiveness of CBTI on SI, and with prior preliminary evidence suggesting that insomnia reduction serves as an important
treatment mechanism [18–20, 22].
Our study offers novel findings. First: prior studies have evaluated the effects of CBTI on SI in a combined sample of patients
with and without SI at baseline. Thus, our study is the first to
test SI alleviation specifically in suicidal patients. Second: prior
studies supporting CBTI for suicide-related outcomes were faceto-face interventions in individual and group formats. Thus, our
study is the first to demonstrate CBTI efficacy for alleviating and

CBTI prevents SI via insomnia remission
CBTI has gained significant interest for its potential role in mitigating the risk of future mental illness, particularly in regard to
depression and anxiety, and has yielded promising results [51–56].
Given that insomnia increases risk for future SI [15–17], it is no
wonder that targeting insomnia via CBTI has been identified as
a potential method to reduce suicide-related outcomes in this
at-risk population [57].
Our study results offer support for CBTI as a preventive measure against suicide for individuals struggling with insomnia,
especially given that remission of insomnia was identified as a
key factor in SI prevention. Although CBTI did not yield a direct
effect on new-onset SI prevention at posttreatment or 1-year
follow-up, we observed a robust indirect effect wherein CBTI
increased the likelihood of insomnia remission, which, in turn,
was associated with lower SI rates at posttreatment for insomnia
remitters (1.5%) relative to insomnia non-remitters (6.5%; RR =
4.33). Data at 1-year follow-up were less clear with per-protocol
analysis results showing no significant SI rate difference between
remitters and non-remitters (4.2% vs 6.4%), whereas ITT analyses
revealed a statistical trend to suggest that insomnia remission
a year after treatment may be related to lower SI rates at 1-year
follow-up (3.8% vs 7.4%).
A limitation that is important to highlight here is our limited
power for testing prevention at 1-year follow-up. A post hoc power
analysis revealed that our logistic regression analysis produced
an OR = 0.496, probability of SI for untreated patients = 7.4% in
the ITT analysis, alpha = 0.05, n = 532, and a binomial X distribution would have β = 0.40 power, which is below the recommended
minimum of β = 0.80. Thus, our ITT result showing a statistical
trend of p = .088 should be interpreted within the context of limited statistical power to detect prevention based on the observed
effect size. Indeed, when evaluating SI rates for patients who
denied SI before treatment, CBTI patients consistently endorsed
new onset SI rates of 4%–5% at posttreatment and a year later. By
comparison, control patients reported new SI rate of 4% at posttreatment then 7%–8% a year later. Taken together, we believe our
study offers strong preliminary support for CBTI preventing SI
through insomnia remission, and that insomnia remission may
confer a degree of long-term protection. Future research utilizing
a larger patient sample is needed to better understand the role of
CBTI in the prevention of suicide-related outcomes.

Treatment mechanisms for reducing SI:
Insomnia is a good start
Prior clinical trials offered preliminary support for alleviating
insomnia as a key mechanism by which insomnia treatment
(psychotherapy, pharmacotherapy) reduces SI [19–21]. The present study added to these findings by showing that insomnia
remission mediates the effects of CBTI on SI alleviation and prevention. Importantly, prior studies show that nocturnal wakefulness represents a robust risk factor for suicide [23, 24], and that
suicides most often occur at night [25]. Future research taking a
more granular approach is needed to evaluate whether insomnia
remission in CBTI reflects the removal of a robust risk factor—i.e.
nocturnal wakefulness—to reduce risk for SI. In other words, it
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Logistic regression revealed that insomnia remitters without pretreatment SI were at substantially lower odds of endorsing new
onset SI after treatment relative to non-remitters (b = −1.74, SE =
0.64, OR = 0.18, 95% CI = 0.05 to 0.62, p = .007). Specifically, 1.5%
of insomnia remitters endorsed new SI after treatment relative
to 6.5% of non-remitters (SI rates by insomnia remission status
in Table 3). Treatment condition remained a nonsignificant predictor in this model (b = 0.64, OR = 1.89, 95% CI = 0.81 to 4.42, p =
.140).

preventing SI using an eHealth digital delivery format. Even if
face-to-face delivery formats are preferred, especially for suicidal
patients, the expansion of these findings to the digital therapeutic format is likely to be a critical and growing element in future
clinical practice given existing shortages of trained CBTI specialists [50].
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Clinical implications and future directions
Role of CBTI in suicide-risk reduction.
Although CBTI significantly reduced SI among patients who initially presented to treatment with suicidal thoughts, many of
these CBTI patients (28%–30%) continued endorsing SI up to a
year after treatment, thereby indicating that standalone CBTI is
insufficient for many suicidal patients with insomnia. Indeed,
CBTI does not adequately address all relevant suicide-risk factors as discussed above. Thus, we believe that CBTI, regardless
of delivery format, is most appropriately delivered as an adjunct
therapy to other mental health interventions for suicidal patients
presenting with insomnia.

Role of CBTI in preventing suicidal thoughts and behaviors.
Our data suggest that CBTI prevents the new development of SI
by helping a large number of patients to fully remit from insomnia. Larger-scale studies are needed to examine more comprehensively the preventive effects of CBTI on suicidal thoughts and
behaviors, including SI intensity, planning, intent, and behaviors.
Accumulating evidence support clinical initiatives to deploy CBTI
more broadly to poorly sleeping individuals—especially those
with other suicide-risk factors, like depression—to mitigate suicide in high-risk groups.

Limitations
Study results should be interpreted in light of important methodological limitations. We have already addressed the lack of
statistical power for detecting SI prevention effects a year after
treatment in the CBTI prevents SI via insomnia remission section
above. Along these lines, our assessment of SI focused on a single
week prior to assessment, and insomnia symptom assessment
focused on a 2-week period. These limited assessment windows

can be considered both a strength and a limitation of this study.
As a strength: prior studies have assessed insomnia and SI over
the past several months or years. In these studies, it is unclear
whether endorsement of both factors represents co-occurrence
or not (e.g. insomnia may have been present for the past week,
whereas SI may have been present a month earlier). In our study,
the confined assessment windows suggest that these experiences
co-occurred. As a limitation, our limited assessment windows
preclude detection of any SI that occurred after treatment but
earlier than a week before follow-up assessment, which would
not have been captured in our study. Future studies evaluating
suicide-related outcomes should consider more frequent assessments. Future insomnia clinical trials utilizing shorter intervals
for assessing SI (momentary, daily, weekly) may capture more
granular insights into how rapidly improvement in insomnia
affects SI [62], and how long these effects may last after treatment. In addition, the present study only assessed SI presence.
More comprehensive assessment of suicide-related outcomes
(SI intensity, suicide planning, intent, attempts, deaths) would
yield greater insights into the potential benefits of digital CBTI
for suicidal thoughts and behaviors. We encourage researchers
to include more comprehensive suicide outcomes assessment in
insomnia clinical trials going forward.
Other key study limitations center on generalizability. Firstly,
men were underrepresented, which is common in clinical trials
of insomnia intervention. Even so, we showed that male insomnia patients were more likely to endorse SI relative to female
insomnia patients, which replicates sex differences in the
broader population [63]. Important to emphasize is that research
also shows that men are more likely to attempt and die by suicide than women [64, 65]. Thus, suicide-focused insomnia studies should consider taking measures to enhance recruitment of
male insomnia patients; this is especially important as women
are more likely to endorse and seek treatment for insomnia [66,
67]. Moreover, only non-Hispanic White and non-Hispanic Black
racial groups were well-represented in our study, which limits
generalizability to other racial groups. Future RCTs evaluating the
role of insomnia therapeutics in suicide management would benefit from recruiting a more racially and ethnically diverse sample.

Conclusions
Evidence supporting the use of insomnia therapeutics, and especially CBTI, in suicide-risk management is growing. Our study
suggests that digital CBTI can be beneficial for reducing and
preventing SI, and that insomnia remission plays a key role in
these effects. Future research is needed to evaluate how to best
incorporate insomnia treatment in suicide management efforts,
both for suicidal patients and for broader prevention initiatives.
In addition, while standard CBTI produces treatment effects on
SI, augmenting CBTI to yield stronger effects on other suicide-related risk factors such as depression and perseverative thinking
may improve its impact on suicide-related outcomes.

Supplementary Material
Supplementary material is available at SLEEP online.
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is possible that insomnia remission is a suicidolytic mechanism
to the extent to which it facilitates the reduction of nocturnal
wakefulness. As insomnia produces effects on suicide-related
outcomes independent of depression and other mental health
conditions [11–13], insomnia therapeutics may be combined with
other independent treatments (e.g. for depression, substance
abuse, borderline personality disorder, etc.) to address multiple
independent SI risk factors.
Despite the large effects of insomnia remission on suicide-related outcomes, we must emphasize that non-sleep-related risk
factors (e.g. mental health symptoms and cognitive-emotional
dysregulation) of course remain critical to suicide intervention.
Important to highlight is that the interplay between sleep-related
factors (e.g. insomnia) and non-sleep-related factors (e.g. cognitive-emotional dysregulation) substantially amplifies SI risk.
Indeed, we have shown that SI rates are highest when patients
endorse both insomnia and high levels of nocturnal perseverative
thinking (e.g. worry and rumination) [58, 59]. Unfortunately, CBTI
exerts modest influence on non-sleep-related SI risk factors such
as depression and perseverative thinking [22, 52, 60, 61]. By extension, it is unsurprising that only insomnia remission was identified
as a mechanism by which CBTI affected SI in the present study (see
Supplementary Materials for exploration of changes in insomnia,
depression, and perseverative thinking as potential treatment
mechanisms for SI). Future studies should evaluate whether
enhanced therapeutic approaches targeting both insomnia symptoms and perseverative thinking may maximize therapeutic benefits for suicide-related outcomes (e.g. lower rates of SI, lower levels
of SI intensity, less likelihood of attempts) in insomnia patients.
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